Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action ...
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in ...
Hosted on MSN
Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance
CEO Mitchell Steiner highlighted Veru's transition to a pure-play late clinical stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, following the divestiture of the ...
Lee Roth - Burns McClellan, Inc. Thanks, operator. As a reminder, a press release summarizing the results of the trial can be found on the Investor Relations section of the company's website. This ...
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, Sept. 11, 2025 ...
LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN ...
Ladies and gentlemen, thank you for joining us, and welcome to Nektar Therapeutics Analyst and Investor Event to discuss REZOLVE-AD maintenance data with atopic dermatitis experts. [Operator ...
In the combined Phase 3 VELA program, all endpoints reached statistical significance with p-values below 0.001, including lesion counts and patient reported outcomes (PROs), as per Table 2.
A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without ...
-ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability ...
-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results